systemHologicMammographyfamily: selenia-dimensions

Hologic Selenia Dimensions 3D

Family: Selenia Dimensions · Modality: Mammography

First FDA-approved commercial digital breast tomosynthesis (DBT) system (PMA-approved 2011). The Dimensions 3D configuration enables tomosynthesis acquisition on top of 2D FFDM — 15° tube sweep over 15 projections acquired in ~3.7 seconds. Anchored the US DBT market for years before the Selenia 3Dimensions succeeded it on a newer detector / reconstruction stack.

Tomosynthesis acquisition

  • 15° arc sweep — the X-ray tube rotates through a narrow arc above the compressed breast; the detector remains stationary.
  • 15 projections — low-dose views acquired across the sweep; reconstructed into ~1 mm slice thickness in the breast.
  • ~3.7-second scan — single breath-hold compatible; compression is maintained throughout.
  • Per-slice reconstruction — resolves lesions that are obscured by overlapping tissue on conventional 2D mammography.

Narrow-angle DBT (Hologic 15°) vs wide-angle DBT (Siemens 50° on the MAMMOMAT Revelation) is the defining architectural split in clinical DBT. Narrow-angle yields thinner slice reconstructions with less out-of-plane artifact and faster acquisition; wide-angle yields different depth-resolution characteristics. Clinical outcome data favor DBT over 2D alone on both approaches.

C-View synthesized 2D

  • C-View — a 2D-equivalent image reconstructed from the DBT dataset, licensed separately from the base tomosynthesis capability.
  • Dose savings — with C-View, the routine screening protocol becomes DBT-only; the separate 2D acquisition and its dose are eliminated, cutting patient dose by roughly half versus a combined 2D + DBT protocol.
  • License discipline — confirming both the DBT and the C-View license on a pre-owned Dimensions 3D is the single most commercially consequential acceptance-test item.

Specs

  • Amorphous-selenium direct-conversion detector
  • 70 µm pixel pitch (2D FFDM and DBT reconstruction)
  • 15° tomosynthesis sweep · 15 projections · ~3.7 sec scan
  • W target with Rh / Ag filtration
  • 70 cm source-to-image distance
  • C-View synthesized 2D (optional licensed)
  • Integrated Affirm biopsy pathway (upright attachment or companion prone system)

Clinical positioning

  • Screening programs transitioning to DBT — Dimensions 3D was the first commercial DBT and defines the reference DBT install in the US through the 2010s.
  • Combination 2D + DBT protocols — baseline Dimensions 3D workflow unless C-View-licensed.
  • C-View-licensed screening — DBT-only protocol at roughly half the combined-protocol dose.
  • Diagnostic work-up — spot compression, additional views, and DBT-guided biopsy routing (to Affirm Prone or upright Affirm attachment).

Relationship to siblings

Regulatory

  • FDA PMA (2011) — the first FDA-approved DBT system. See FDA PMA.
  • MQSA — mammography facilities must be MQSA-certified; DBT-specific CEU and QA requirements apply. See MQSA.

Related